1 / 14

‘Indirect’ Mutation Analysis in Cancer Families

‘Indirect’ Mutation Analysis in Cancer Families. SCOBEC & Birmingham Cancer Training Day 6 th June 2007 Nicole Motton. Origin of this Approach to Mutation Analysis. Short Report by D G Cruger et al . Clinical Genetics 2005: 68: 228-233.

katina
Download Presentation

‘Indirect’ Mutation Analysis in Cancer Families

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. ‘Indirect’ Mutation Analysis in Cancer Families SCOBEC & Birmingham Cancer Training Day 6th June 2007 Nicole Motton

  2. Origin of this Approach to Mutation Analysis • Short Report by D G Cruger etal. • Clinical Genetics 2005: 68: 228-233. • ‘Indirect’ BRCA1/2 testing. A useful approach in hereditary breast and ovarian cancer families without a living affected relative.

  3. Introduction • Currently genetic testing is offered based on the chance of identifying a disease-causing mutation • Several models can be used and a threshold of 10% for mutation analysis suggested for each gene • Practise is to test cancer families where an affected member will provide a blood sample • Testing a single unaffected member from a high risk family is limited if no mutation is found • Could be an undetectable mutation or a mutation in an unknown gene • Therefore the risk will still be thought to be increased

  4. ‘Indirect’ Mutation Testing • For a large number of families no sample is available from the affected family member so no mutation screening will be offered • Even if affected relative DNA is available they could be a phenocopy • Many of these families have a history of cancer and are at very high risk of harbouring a mutation • May consider prophylatic surgery and in theory 50% may not carry a mutation • A method of genetic testing for high risk breast & ovarian cancer families where no DNA is available from affected relatives

  5. ‘Indirect’ Mutation Testing Strategy • An alternative approach is by offering mutation screening to unaffected relatives • Test ≥2 unaffected relatives at 50% risk of being heterozygous for a potential mutation • Gives a chance of up to 99% of finding a disease-causing mutation that would have been found in an affected family member • By testing more relatives the probability of detecting a mutation increases

  6. Probability of identifying a mutation present in an affected relative by number of unaffected individuals tested. Unaffected individuals must be first degree relatives at 50% heterozygous risk (1-0.5n)

  7. Case Studies • Apply to Breast/Ovarian cancer families and HNPCC families (esp. with MSI & IHC studies available) • 3 Breast/Ovarian cancer families and 3 HNPCC families in which this approach has been successful • All families fulfilled local guidelines for mutation screening but no affected relatives were available to give DNA

  8. BROV Family 1 p.Leu2092ProfsX7 exon 11 BRCA2 No Mutation 75% chance of detecting a mutation

  9. BROV Family 2 p.Leu1098SerfsX4 exon 11 BRCA1 p.Leu1098SerfsX4 exon 11 BRCA1 75% chance of detecting a mutation

  10. BROV Family 3 Missense c.1206C>A; p.Ser326Arg exon 10 BRCA2 Declined testing Missense c.1206C>A; p.Ser326Arg exon 10 BRCA2 No Mutation 87.5% chance of detecting a mutation

  11. Loss MSH2 MSI +ve HNPCC Family 1 87.5% chance of detecting a mutation p.Lys675X Exon 13 hMSH2 No Mutation p.Lys675X Exon 13 hMSH2

  12. Loss MSH2 MSI +ve HNPCC Family 2 Deletion exons 11-16 in hMSH2 No Mutation 75% chance of detecting a mutation

  13. Loss MSH2 MSI +ve No sample No sample HNPCC Family 3 Duplication exons 1-6 in hMSH2 50% chance of detecting a mutation

  14. Summary • In all but one of these families deleterious mutations were identified • Missense mutations are difficult to interpret especially if no DNA is available from an affected member • Proven to be a very useful technique • Allows family members to make decisions about risk-reducing surgery and surveillance based on their own mutation status • Allows presymptomatic testing to become available • Essentially performing presymptomatic testing but in an 8 week turnaround time • Thorough genetic counselling before consenting

More Related